Compare AUDC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | TRDA |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | Israel | United States |
| Employees | N/A | 152 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.9M | 254.7M |
| IPO Year | 2000 | 2021 |
| Metric | AUDC | TRDA |
|---|---|---|
| Price | $9.12 | $6.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.50 | ★ $21.00 |
| AVG Volume (30 Days) | 109.8K | ★ 603.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | $4.24 | $39.97 |
| Revenue Next Year | $2.18 | $50.80 |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.95 | $4.93 |
| 52 Week High | $11.48 | $16.45 |
| Indicator | AUDC | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 32.62 |
| Support Level | $8.46 | $5.58 |
| Resistance Level | $9.82 | $6.90 |
| Average True Range (ATR) | 0.33 | 0.81 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 94.55 | 8.23 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.